About UnigeneUnigene Laboratories.

About UnigeneUnigene Laboratories, a biopharmaceutical company focusing on the oral and nasal delivery of large market peptide drugs. Due to the size of the worldwide osteoporosis market Unigene targeting. Its initial efforts on developing calcitonin and PTH-based therapies Fortica Unigene nasal calcitonin for the treatment of postmenopausal osteoporosis, received FDA approval and Unigene in August 2005. Unigene has licensed U.S. Rights for Fortica Upsher-Smith Laboratories, worldwide rights for the oral PTH technology GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene patented oral delivery technology has successfully delivered, in preclinical and / or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics.

Findings in the report evidence that calcitonin has also demonstrated a reduction among fracture risk in postmenopausal women and men. The global history of calcitonin products has an impressive safety profile, with products that are administered to patients in practice for more than 35 years without significant side effects.Andreas Meyer-Lindenberg and his colleagues have ready to buy brains in adults with Williams syndrome while they seen stock images from emotionally faces of and creepy scenes.

Both comments and pings are currently closed.

Comments are closed.

Powered by WordPress | Designed by: redshirtarmy.com | Thanks to redshirtarmy.com